Literature DB >> 24801586

Surgical remission of Cushing's syndrome reduces cardiovascular risk.

M Terzolo1, B Allasino1, A Pia1, G Peraga1, F Daffara1, F Laino1, A Ardito1, A Termine1, P Paccotti1, P Berchialla1, G Migliaretti1, G Reimondo2.   

Abstract

OBJECTIVE: Recent studies have questioned the reversibility of complications of Cushing's syndrome (CS) after successful surgical treatment. The aim of this study was to assess the outcome of patients with CS who achieved disease remission compared with those patients with persistent hypercortisolism and matched controls.
DESIGN: A retrospective study of 75 patients with CS followed at an academic center.
METHODS: Cardiovascular risk profile was evaluated in 51 patients with CS in remission (group 1) and 24 patients with persistent disease (group 2) and compared with 60 controls. Mortality of patients with CS was compared with the background population.
RESULTS: In group 1, the frequency of cardiovascular risk factors dropped after disease remission even if it remained higher at the last follow-up than in the control group. In group 2, the frequency of cardiovascular risk factors remained unchanged during follow-up. The rate of cardiovascular and thromboembolic events was higher in group 2 than in group 1, as was the mortality rate (two deaths in group 1 and nine in group 2; ratio of two SMRs, 0.11; 95% CI, 0.011-0.512). Survival was significantly longer in group 1 than in group 2 (87 months, 80-98 vs 48 months, 38-62; P<0.0001).
CONCLUSIONS: Successful surgical treatment of hypercortisolism significantly improves cardiovascular risk and may reduce the mortality rate. Patients with persistent disease have increased morbidity and mortality when compared with patients in remission.
© 2014 European Society of Endocrinology.

Entities:  

Mesh:

Year:  2014        PMID: 24801586     DOI: 10.1530/EJE-13-0555

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  QT interval instability and variability in dogs with naturally-occurring hypercortisolism.

Authors:  Beatriz de Carvalho Pato Vila; Marcela Sigolo Vanhoni; Marlos Gonçalves Sousa
Journal:  Vet Res Commun       Date:  2022-05-16       Impact factor: 2.459

Review 2.  Cardiovascular risk and mortality in patients with active and treated hypercortisolism.

Authors:  Dingfeng Li; Omar M El Kawkgi; Andres F Henriquez; Irina Bancos
Journal:  Gland Surg       Date:  2020-02

3.  Lack of functional remission in Cushing's syndrome.

Authors:  M Vermalle; M Alessandrini; T Graillon; N C Paladino; K Baumstarck; F Sebag; H Dufour; T Brue; F Castinetti
Journal:  Endocrine       Date:  2018-07-17       Impact factor: 3.633

Review 4.  The risks of overlooking the diagnosis of secreting pituitary adenomas.

Authors:  Thierry Brue; Frederic Castinetti
Journal:  Orphanet J Rare Dis       Date:  2016-10-06       Impact factor: 4.123

5.  The Effect of Curative Treatment on Hyperglycemia in Patients With Cushing Syndrome.

Authors:  Justine Herndon; Ravinder Jeet Kaur; Mark Romportl; Emily Smith; Amy Koenigs; Brenda Partlow; Leonardo Arteaga; Irina Bancos
Journal:  J Endocr Soc       Date:  2021-12-02

6.  The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality.

Authors:  Padiporn Limumpornpetch; Ann W Morgan; Ana Tiganescu; Paul D Baxter; Victoria Nyawira Nyaga; Mar Pujades-Rodriguez; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

7.  Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.

Authors:  Henry G Fein; T Brooks Vaughan; Harvey Kushner; David Cram; Dat Nguyen
Journal:  BMC Endocr Disord       Date:  2015-10-27       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.